Abstract
Background: Several COVID-19 vaccines have been approved. The mRNA vaccine from Pfizer/BioNTech (Comirnaty, BNT162b2; BNT) and the vector vaccine from AstraZeneca (Vaxzevria, ChAdOx1; AZ) have been widely used. mRNA vaccines induce high antibody and T cell responses, also to SARS-CoV-2 variants, but are costlier and less stable than the slightly less effective vector vaccines. For vector vaccines, heterologous vaccination schedules have generally proven more effective than homologous schedules.
Methods: In the HEVACC three-arm, single-blinded, adaptive design study (ClinicalTrials.gov Identifier: NCT04907331 ), participants between 18 and 65 years with no prior history of SARS-CoV-2 infection and a first dose of AZ or BNT were included. The AZ/AZ and the AZ/BNT arms were randomized (in a 1:1 ratio stratified by sex and trial site) and single-blinded, the third arm (BNT/BNT) was observational. We compared the reactogenicity between the study arms and hypothesized that immunogenicity was higher for the heterologous AZ/BNT compared to the homologous AZ/AZ regimen using neutralizing antibody titers as primary endpoint.
Findings: This interim analysis was conducted after 234 participants had been randomized and 254 immunized (N=109 AZ/AZ, N=115 AZ/BNZ, N=30 BNT/BNT). Heterologous AZ/BNT vaccination was well tolerated without study-related severe adverse events. Neutralizing antibody titers on day 30 were statistically significant higher in the AZ/BNT and the BNT/BNT groups than in the AZ/AZ group, for B.1.617.2 (Delta) AZ/AZ median reciprocal titer 75.9 (99.9% CI 58.0 – 132.5), AZ/BNT 571.5 (99.9% CI 396.6 – 733.1), and BNT/BNT 404.5 (99.9% CI 68.3 – 1024). Similarly, the frequency and multifunctionality of spike-specific T cell responses was comparable between the AZ/BNT and the BNT/BNT groups, but lower in the AZ/AZ vaccinees.
Interpretation: This study clearly shows the immunogenicity and safety of heterologous AZ/BNT vaccination and encourages further studies on heterologous vaccination schedules.
Funding: This work was supported by the Medical University of Innsbruck, and partially funded by NIAID contracts No. 75N9301900065, 75N93021C00016, and 75N93019C00051.
Keywords: BNT162b2; ChAdOx1; Heterologous COVID-19 vaccination; Neutralizing antibodies; SARS-CoV-2; T cells.
【저자키워드】 SARS-CoV-2, Neutralizing antibodies, T cells., BNT162b2, breath, ChAdOx1, Heterologous COVID-19 vaccination, 【초록키워드】 COVID-19, Vaccine, COVID-19 vaccine, vaccination, immunogenicity, reactogenicity, Trial, adaptive, Vaccines, Neutralizing antibodies, antibody, mRNA vaccine, T cells, SARS-COV-2 infection, Delta, B.1.617.2, mRNA vaccines, BNT162b2, Pfizer, Randomized, T cell, SARS-CoV-2 variants, response, T cell responses, Antibody titer, group, homologous, university, ChAdOx1, AstraZeneca, Antibody titers, Heterologous, Neutralizing antibody titer, Pfizer/BioNTech, Frequency, primary endpoint, regimen, first dose, neutralizing antibody titers, participant, interim analysis, severe adverse events, NIAID, vaccinees, vaccination schedule, Arm, effective, immunized, approved, conducted, supported, median, less, induce, comparable, groups, statistically significant, 1:1, BNT, spike-specific T cell, stratified by sex, 【제목키워드】 immune response, vaccination, Trial, Randomized, homologous, ChAdOx1, Pragmatic, induce,